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Background
The novel chimeric natriuretic peptide, CD-NP, is a Mayo-
designed cGMP-activating synthetic peptide that consists
of the 22-amino-acid (AA) residues of C-type natriuretic
peptide (CNP) and the 15-AA C-terminal extension of
Dendroaspis natriuretic peptide (DNP) [1]. The rationale
for the design of CD-NP was to transform CNP, which
activates natriuretic peptide receptor-B (NPR-B) and is
natriuretic, diuretic and less hypotensive than ANP and
BNP which activate NPR-A into a CNP-like peptide with
added renal actions. The goal of this investigation was to
directly compare the cardiorenal profile of CD-NP to that
of CNP.
Materials and methods
Normal anesthetized dogs were given CD-NP 50 ng/kg/
min i.v. (n = 10) or an equimolar dose of CNP (29.3 ng/
kg/min i.v., n = 7) for 75 min. Four 30-min clearances
were performed at the following time points: pre-infusion
(pre-I), at 30 and 60 min of I, and post-I. Blood and urine
samples were collected for each clearance. Glomerular fil-
tration rate was determined by inulin clearance. Compar-
isons were made within group vs pre-I (mean ± SEM, P <
0.05*, <0.01†) and between groups (P < 0.05‡, <0.01§,
<0.001) using repeated measures ANOVA.
Results
CD-NP significantly increased plasma cGMP (7 ± .4 to 25
± 3† to 36 ± 3† to 23 ± 3† pmol/ml) and urinary cGMP
excretion (978 ± 145 to 3170 ± 205†‡ to 5919 ± 616† to
3077 ± 298† pmol/min) versus CNP (7.8 ± .8 to 9.1 ± .3 to
10.1 ± .6† to 8.1 ± .6 pmol/ml; 1099 ± 101 to 1193 ± 119
to 1301 ± 142 to 1003 ± 146 pmol/min, respectively).
CD-NP significantly increased urinary sodium excretion
(19 ± 4 to 168 ± 24†§ to 237 ± 26† to 96 ± 12† μeq/min)
versus CNP (39 ± 14 to 68 ± 12 to 85 ± 31 to 81 ± 29 μeq/
min). Urine flow (ml/min) was augmented by CD-NP
(0.2 ± .06 to 1.3 ± .2† to 1.8 ± .3† to 0.8 ± .2†) and CNP
(0.5 ± .1 to 1.0 ± .2 to 1.3 ± .3* to 1.0 ± .3). Glomerular
filtration rate was enhanced by CD-NP (37 ± 2*‡ to 48 ±
3† to 51 ± 3† to 53 ± 4† ml/min) and was preserved by CNP
(55 ± 5 to 57 ± 6 to 52 ± 4 to 50 ± 6 ml/min). Pulmonary
capillary wedge pressure was significantly reduced by CD-
NP (5.7 ± .7 to 4.1 ± 1* to 3.2 ± .7†‡ to 4.3 ± .8 mmHg),
but not by CNP (5.8 ± .7 to 5.7 ± .8 to 6.7 ± .7 to 7.4 ± .9†
mmHg). Right atrial pressure was significantly reduced by
CD-NP (1.8 ± .4 to 1.1 ± .4† to 0.9 ± .5†§ to 1.3 ± .5
mmHg), but not by CNP (2.7 ± .3 to 2.6 ± .3 to 3.2 ± .3 to
3.9 ± .4† mmHg). Neither CD-NP nor CNP induced sys-
temic hypotension (mean arterial pressure 127 ± 4 to 124
± 5 to 122 ± 6 to 126 ± 7 mmHg; 121 ± 5 to 126 ± 4 to 127
± 5 to 126 ± 4 mmHg, respectively).
Conclusion
This study demonstrates the successful transformation of
CNP to a CNP-like peptide, which is cGMP-activating,
natriuretic, diuretic, GFR-enhancing, and cardiac unload-
ing, and has minimal blood pressure lowering effects. This
cardiorenal profile of CD-NP is highly attractive as a drug
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for the treatment of acute decompensated heart failure,
warranting further investigation.
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